True Wealth Design
NBIX icon

True Wealth Design’s Neurocrine Biosciences NBIX Stock Holding History

True Wealth Design’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$94.8K Sell
668
-396
-37% -$63.7K 0.02% 300
2026
Q2 		$179K Sell
1,064
-171
-14% -$25.4K 0.04% 133
2026
Q1 		$163K Buy
1,235
+270
+28% +$35.8K 0.05% 120
2025
Q4 		$137K Buy
965
+14
+1% +$2.03K 0.04% 130
2025
Q3 		$134K Buy
951
+609
+178% +$82.5K 0.04% 115
2025
Q2 		$43K Buy
342
+316
+1,215% +$36.2K 0.02% 222
2025
Q1 		$2.88K Sell
26
-418
-94% -$53K ﹤0.01% 879
2024
Q4 		$60.6K Sell
444
-148
-25% -$18.3K 0.02% 133
2024
Q3 		$68.2K Buy
592
+587
+11,740% +$80.5K 0.03% 88
2024
Q2 		$689 Buy
5
+2
+67% +$274 ﹤0.01% 598
2024
Q1 		$414 Buy
3
+1
+50% +$137 ﹤0.01% 666
2023
Q4 		$264 Hold
2
– – ﹤0.01% 635
2023
Q3 		$225 Hold
2
– – ﹤0.01% 617
2023
Q2 		$189 Hold
2
– – ﹤0.01% 658
2023
Q1 		$203 Hold
2
– – ﹤0.01% 727
2022
Q4 		$239 Buy
+2
New +$234 ﹤0.01% 636

Other funds holding NBIX

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $61B AUM 26.91% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $118B AUM 40.52% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
IEQ Capital
IEQ Capital Foster City, California $23.5B AUM 29.01% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
GW&K Investment Management
GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $45.5B AUM 15.2% 1-Year Est. Return

True Wealth Design's NBIX Position: Q3 2026 in Review

True Wealth Design reduced its Neurocrine Biosciences (NBIX) stake by 37% in Q3 2026, selling an estimated $63.7K and leaving 668 shares worth $94.8K. The position accounts for 0.02% of the portfolio, ranked #300.

True Wealth Design first reported a position in NBIX in Q4 2022 and has held it in 16 quarters since. The position peaked at $179K in Q2 2026. 446 funds tracked by Wall St. Rank hold NBIX as of Q3 2026.

  • True Wealth Design held 668 shares of Neurocrine Biosciences worth $94.8K as of Q3 2026.
  • True Wealth Design sold 396 Neurocrine Biosciences shares in Q3 2026, an estimated $63.7K.
  • Neurocrine Biosciences made up 0.02% of True Wealth Design's portfolio in Q3 2026, its #300 holding.
  • True Wealth Design first reported a position in Neurocrine Biosciences in Q4 2022 and has held it in 16 quarters since.
  • True Wealth Design's Neurocrine Biosciences position peaked at $179K in Q2 2026.
  • 446 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2026.

Based on True Wealth Design's 13F filing for Q3 2026, filed 13 Oct 2026.